CY2012014I1 - Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης - Google Patents
Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρηςInfo
- Publication number
- CY2012014I1 CY2012014I1 CY2012014C CY2012014C CY2012014I1 CY 2012014 I1 CY2012014 I1 CY 2012014I1 CY 2012014 C CY2012014 C CY 2012014C CY 2012014 C CY2012014 C CY 2012014C CY 2012014 I1 CY2012014 I1 CY 2012014I1
- Authority
- CY
- Cyprus
- Prior art keywords
- tegafur
- administration
- toxicity due
- gastrointestinal toxicity
- reducing gastrointestinal
- Prior art date
Links
- 206010059024 Gastrointestinal toxicity Diseases 0.000 title 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 title 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title 1
- 229960001674 tegafur Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56618004P | 2004-04-29 | 2004-04-29 | |
| PCT/JP2005/008450 WO2005105086A1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2012014I1 true CY2012014I1 (el) | 2016-04-13 |
| CY2012014I2 CY2012014I2 (el) | 2016-04-13 |
Family
ID=35241420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100222T CY1112451T1 (el) | 2004-04-29 | 2012-03-07 | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης |
| CY2012014C CY2012014I2 (el) | 2004-04-29 | 2012-05-31 | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100222T CY1112451T1 (el) | 2004-04-29 | 2012-03-07 | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080166427A1 (el) |
| EP (1) | EP1750703B1 (el) |
| JP (1) | JP5376758B2 (el) |
| AT (1) | ATE540679T1 (el) |
| AU (1) | AU2005237364B2 (el) |
| CY (2) | CY1112451T1 (el) |
| DK (1) | DK1750703T3 (el) |
| ES (1) | ES2378072T3 (el) |
| HR (1) | HRP20120293T1 (el) |
| ME (1) | ME01335B (el) |
| PL (1) | PL1750703T3 (el) |
| PT (1) | PT1750703E (el) |
| RS (1) | RS52217B (el) |
| RU (1) | RU2348409C2 (el) |
| SI (1) | SI1750703T1 (el) |
| WO (1) | WO2005105086A1 (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201039816A (en) * | 2009-05-13 | 2010-11-16 | Taiho Pharmaceutical Co Ltd | Treatment of diffuse-type gastric cancers using S-1 and cisplatin |
| CN102648412A (zh) * | 2009-07-17 | 2012-08-22 | 美瑞德生物工程公司 | 5-fu的检测方法 |
| WO2011022174A1 (en) * | 2009-08-21 | 2011-02-24 | Myriad Genetics, Inc. | Method of processing blood samples containing 5-fu |
| EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422784A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422815A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| RU2697480C2 (ru) * | 2014-03-06 | 2019-08-14 | Юниверсити Оф Саутерн Калифорния | Применение режима краткосрочного голодания в сочетании с ингибиторами киназ для усовершенствования традиционной химио-лекарственной эффективности и пригодности и обращения вспять побочных эффектов от киназ в нормальных клетках и тканях |
| EP3122354B1 (en) | 2014-03-28 | 2022-06-15 | Universita' degli Studi di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| WO2016175324A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| JP6439761B2 (ja) * | 2016-08-09 | 2018-12-19 | トヨタ自動車株式会社 | ＮＯｘ吸蔵還元触媒の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635946A (en) * | 1969-07-22 | 1972-01-18 | Solomon Aronovich Giller | N1-(2'-furanidyl)-derivatives of 5-substituted uracils |
| DK175432B1 (da) * | 1984-10-30 | 2004-10-18 | Otsuka Pharma Co Ltd | Middel til forögelse af anticancervirkningen af anticancerforbindelser |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| NL194430C (nl) * | 1989-01-05 | 2002-04-04 | Otsuka Pharma Co Ltd | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. |
| ATE173165T1 (de) * | 1991-05-27 | 1998-11-15 | Taiho Pharmaceutical Co Ltd | Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren |
-
2005
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 RS RS20120127A patent/RS52217B/en unknown
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es active Active
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en active Application Filing
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en active Active
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
-
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-04-03 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005105086A1 (en) | 2005-11-10 |
| AU2005237364B2 (en) | 2010-07-08 |
| ATE540679T1 (de) | 2012-01-15 |
| JP2007534634A (ja) | 2007-11-29 |
| RS52217B (en) | 2012-10-31 |
| PT1750703E (pt) | 2012-02-23 |
| ES2378072T3 (es) | 2012-04-04 |
| EP1750703A1 (en) | 2007-02-14 |
| PL1750703T3 (pl) | 2012-05-31 |
| AU2005237364A1 (en) | 2005-11-10 |
| US20080166427A1 (en) | 2008-07-10 |
| EP1750703B1 (en) | 2012-01-11 |
| RU2006142101A (ru) | 2008-06-20 |
| EP1750703A4 (en) | 2008-02-27 |
| RU2348409C2 (ru) | 2009-03-10 |
| ME01335B (me) | 2013-12-20 |
| CY1112451T1 (el) | 2015-12-09 |
| CY2012014I2 (el) | 2016-04-13 |
| DK1750703T3 (da) | 2012-05-07 |
| SI1750703T1 (sl) | 2012-02-29 |
| JP5376758B2 (ja) | 2013-12-25 |
| HRP20120293T1 (hr) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2012014I1 (el) | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης | |
| NL300885I2 (nl) | Irinotecansucrosofaatzout | |
| IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
| DK2783682T3 (da) | Farmaceutisk sammensætning omfattende pimobendan | |
| ATE383361T1 (de) | Pyrrazolopyrimidinderivate | |
| ATE394399T1 (de) | Tetrahydropyridoindolderivate | |
| DK2253614T3 (da) | IAP-inhibitorer | |
| DK1778718T3 (da) | Iap-inhibitorer | |
| ATE553079T1 (de) | Heteroarylphenylharnstoffderivat | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| DK1919907T5 (da) | Heterocyklisk forbindelse | |
| ATE417830T1 (de) | Sulfonylbenzimidazolderivate | |
| DE602005025715D1 (de) | Kondensator | |
| BRPI0511900A (pt) | composições farmacêuticas | |
| ATE512960T1 (de) | Pyrimidinderivate | |
| ATE412651T1 (de) | Pyrrolopyridinderivate | |
| ATE404546T1 (de) | Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen | |
| ATE430142T1 (de) | Phenylpiperazin-methanon-derivate | |
| DE602005001253D1 (de) | Leichtausteckbarer Verbinder | |
| ATE404542T1 (de) | 4-phenylpyrimidin-2-carbonitrilderivate | |
| NO20070299L (no) | Novel heterocyclic compounds | |
| DK1740574T3 (da) | 4-amino-5-cyanopyrimidinderivater | |
| ITMI20042238A1 (it) | Composti per fluoropolirterei | |
| SE0601411L (sv) | Förfarande vid beredning |